This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Genetics of Fatty Liver Disease in Children

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Sonia Caprio, Yale University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Sonia Caprio, Yale University Identifier:
First received: July 15, 2013
Last updated: April 25, 2017
Last verified: April 2017

This is a study to investigate genetic predisposition to hepatic steatosis and the expression of gluconeogenic and lipogenic genes in livers of obese children and adolescents.

Hypothesis 1: Common variants recently associated with variation in plasma TG levels identified in Genome Wide Association Studies (GWAS) (such as GCKR, PNPLA3) can affect accumulation of fat and subsequent development of Non Alcoholic Fatty Liver Disease (NAFLD). Gene variants act in additive or synergistic manner with progressive liver fat accumulation per additional risk allele.

Hypothesis 2: With increase in hepatic fat content NASH and fibrosis will increase. Furthermore, expression of lipogenic markers (SREBP1c) will increase.

Condition Intervention
Non Alcoholic Fatty Liver Disease Other: ogtt Other: genotyping Other: abdominal and liver magnetic resonance imaging Other: stool sample Other: liver biopsy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Genetics of Fatty Liver Disease in Childhood Obesity.

Resource links provided by NLM:

Further study details as provided by Sonia Caprio, Yale University:

Primary Outcome Measures:
  • gene expression [ Time Frame: Baseline ]
    gene mutation allele variation identification measure via gene extraction

Secondary Outcome Measures:
  • hepatic fat content [ Time Frame: 2 years ]
    Abdominal MRI to measure liver fat and subcutaneous and visceral fat ratio done at baseline and 2 year follow up

  • glucose tolerance [ Time Frame: 2 years ]
    glucose tolerance status measured by 3 hour oral glucose tolerance test done at baseline and 2 year follow up

Other Outcome Measures:
  • DNA gene sequencing of intestinal bacteria's [ Time Frame: 2 years ]
    Measure microbiota diversity via stool samples to understand variance of triglycerides accumulation in liver

  • Use liver biopsy specimen to assess differences in gene expression, as well as inflammation. [ Time Frame: As indicated by Pediatric Hepatolgist ]
    liver biopsy tissue obtained when subject is scheduled for pre-ordered biopsy by hepatologist

Biospecimen Retention:   Samples With DNA

Estimated Enrollment: 1000
Study Start Date: July 2011
Estimated Study Completion Date: December 2020
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Pediatric NAFLD Cohort
Overweight and obese children and adolescents at risk for non alcoholic fatty liver disease will undergo oral glucose tolerance testing (ogtt), genotyping, abdominal and liver magnetic resonance imaging (mri), and will provide a stool sample at baseline and at 2 year follow up. A small subset will undergo liver biopsy to test for hepatic steatosis and nonalcoholic steatohepatitis.
Other: ogtt
oral glucose tolerance test
Other: genotyping
genotyping to look for risk alleles
Other: abdominal and liver magnetic resonance imaging
magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
Other: stool sample
stool sample taken to investigate metabolites
Other: liver biopsy
liver biopsy to examine for cellular change and steatosis

Detailed Description:
To establish a cohort of obese youths to prospectively analyze potential factors (genetic and nutritional factors) that might affect the expression and progression of NAFLD. This study will determine genetic markers and their ability to convey susceptibility to NAFLD in obese children and adolescents. Furthermore, potential mechanisms that might contribute to the accumulation of hepatic Triglyceride (TG) accumulation will be, for the first time, assessed by genotyping. Additionally, we will examine the presence of intestinal microbiome in the development of fatty liver through stool collection.

Ages Eligible for Study:   7 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The majority of the research subjects will be recruited from the Yale Pediatric Obesity Clinic and the Endocrine Clinic.

Inclusion Criteria:

  • between 7 and 18 years of age,
  • overweight or obese with a BMI greater than the 85th percentile for age and gender, and
  • be otherwise healthy.

Exclusion Criteria:

  • the use of any medication that alters liver function, blood pressure, glucose or lipid metabolism and
  • no use of any antipsychotic medication
  • Youth on chronic anti-inflammatory medications or who consume alcohol are also excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01966627

Contact: Bridget Pierpont, MA 203-785-6459

United States, Connecticut
Yale University Recruiting
New Haven, Connecticut, United States, 06510
Contact: Bridget Pierpont, M.A.    203-785-2942      
Principal Investigator: Sonia Caprio, M.D.         
Sponsors and Collaborators
Yale University
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Sonia Caprio, M.D. Yale University
  More Information

Responsible Party: Sonia Caprio, Principal Investigator, Yale University Identifier: NCT01966627     History of Changes
Other Study ID Numbers: 1104008388
R01HD040787 ( U.S. NIH Grant/Contract )
Study First Received: July 15, 2013
Last Updated: April 25, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Sonia Caprio, Yale University:
non alcoholic fatty liver
childhood obesity
genetic variants

Additional relevant MeSH terms:
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases
Liver Extracts
Hematinics processed this record on August 21, 2017